JENNIFER CECIL: Open Payments
NPI 1437450822 · MAGNA, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$453 in 8 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $453
Food & beverage: $453
| Company | Payments | Amount |
|---|---|---|
| Edwards Lifesciences Corporation | 1 | $202 |
| GlaxoSmithKline, LLC. | 1 | $91 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $90 |
| Astellas Pharma US Inc | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Smith+Nephew, Inc. | 1 | $17 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
Products named: SAPIEN 3 Ultra RESILIA, AREXVY, CAPLYTA, Veozah, GVOKE HYPOPEN, STRAVIX, BREZTRI.
Industry payments across UT — which companies pay providers there.
